Mexin Medicaments Profile
Key Indicators
- Authorised Capital ₹ 6.00 Cr
as on 17-11-2024
- Paid Up Capital ₹ 4.25 Cr
as on 17-11-2024
- Company Age 44 Year, 11 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 8.37 Cr
as on 17-11-2024
- Revenue -4.22%
(FY 2023)
- Profit -66.42%
(FY 2023)
- Ebitda -72.67%
(FY 2023)
- Net Worth -17.35%
(FY 2023)
- Total Assets -17.81%
(FY 2023)
About Mexin Medicaments
The Company is engaged in the Financial Services Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 6.00 Cr and a paid-up capital of Rs 4.25 Cr.
The company currently has active open charges totaling ₹8.37 Cr.
Premchand Godha, Prashant Godha, and Pranay Godha serve as directors at the Company.
- CIN/LLPIN
U24100MH1980PTC022105
- Company No.
022105
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jan 1980
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Mexin Medicaments?
Board Members(3)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Premchand Godha  | Director | 25-Sep-2021 | Current |
| Prashant Godha | Director | 07-Sep-2015 | Current |
| Pranay Godha | Director | 26-Mar-1999 | Current |
Financial Performance of Mexin Medicaments.
Mexin Medicaments Private Limited, for the financial year ended 2023, experienced Minor drop in revenue, with a 4.22% decrease. The company also saw a substantial fall in profitability, with a 66.42% decrease in profit. The company's net worth observed a substantial decline by a decrease of 17.35%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Mexin Medicaments?
In 2023, Mexin Medicaments had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Ipca Laboratories LimitedActive 75 years 2 monthsPremchand Godha, Prashant Godha and 1 more are mutual person
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
The Vysya Bank Ltd. Creation Date: 31 Mar 1997 | ₹4.25 Cr | Open |
State Bank Of India Creation Date: 27 Nov 1994 | ₹1.18 Cr | Open |
Union Bank Of India Creation Date: 09 Aug 1994 | ₹4.90 M | Open |
How Many Employees Work at Mexin Medicaments?
Unlock and access historical data on people associated with Mexin Medicaments, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Mexin Medicaments, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Mexin Medicaments's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
